Literature DB >> 25751237

A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era.

Chiara Mameli1, Valentina Fabiano, Laura Daprai, Giorgio Bedogni, Marino Faccini, Maria Laura Garlaschi, Francesca Penagini, Dario Dilillo, Erminio Torresani, Maria Gramegna, Gian Vincenzo Zuccotti.   

Abstract

Few epidemiological data are available after the introduction of the 13-valent pneumococcal vaccine (PCV13) in 2010. We performed repeat nasopharyngeal swabs and evaluated the serotype distribution of Streptococcus pneumoniae (SP) and its association with PCV13 vaccine status in healthy Italian children aged 3-59 months. SP serotypes were assessed by the Quellung reaction. 618 children appropriately (28%) or incompletely (72%) vaccinated for age with PCV13 were available at baseline (T0). 515 were re-evaluated at 6 months from baseline (T6) and 436 at 12 months from baseline (T12). The percentage of appropriately vaccinated subjects at T0, T6 and T12 was 28%, 67% and 92%, respectively. Random effects logistic regression models with robust 95% confidence intervals was used to estimate the time-related changes in SP and PCV13 carriage and marginal probabilities were obtained from such models. The age-corrected probability of SP carriage was 0.31 (95% CI 0.22 - 0.41) at T0, 0.32 (0.24 - 0.40) at T6 and 0.28 (0.20 - 0.35) at T12. The probability of PCV13 serotypes carriage was 0.025 (0.001 - 0.050) at T0, 0.018 (0.001 - 0.039) at T6 and 0.010 (0.001 - 0.023) at T12. A decrease in PCV13 serotypes and a shift in non-PCV13 serotypes colonization was observed. In particular, the 15A serotype accounted for 4%, 8% and 23% of SP isolates at T0, T6 and T12, respectively. In conclusion, the benefits of the PCV13 vaccination on SP carriage increase with increasing coverage rates. The shift of SP isolates toward non-PCV13 serotypes needs to be studied further.

Entities:  

Keywords:  13-valent pneumococcal conjugate vaccine; CI, confidence interval; IPD, invasive pneumococcal disease; MAR, missing at random; N, number; OR, odds ratio; PCV13, pneumococcal 13-valent vaccine; PCV7, pneumococcal 7-valent vaccine; SP, Streptococcus pneumoniae; Streptococcus pneumoniae; VT, vaccine type; children; cohort study; epidemiology; nasopharyngeal carriage

Mesh:

Substances:

Year:  2015        PMID: 25751237      PMCID: PMC4514434          DOI: 10.1080/21645515.2015.1010945

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  33 in total

1.  Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.

Authors:  Shalom Ben-Shimol; Noga Givon-Lavi; Eugene Leibovitz; Simon Raiz; David Greenberg; Ron Dagan
Journal:  Clin Infect Dis       Date:  2014-08-25       Impact factor: 9.079

2.  Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

Authors:  Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-03       Impact factor: 3.164

3.  Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France.

Authors:  Corinne Levy; Emmanuelle Varon; Capucine Picard; Stéphane Béchet; Alain Martinot; Stéphane Bonacorsi; Robert Cohen
Journal:  Pediatr Infect Dis J       Date:  2014-12       Impact factor: 2.129

4.  Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.

Authors:  Chiara Azzari; Federico Martinón-Torres; Heinz-Josef Schmitt; Ron Dagan
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

5.  Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae.

Authors:  Katherine L O'Brien; Hanna Nohynek
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

6.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.

Authors:  R Dagan; R Melamed; M Muallem; L Piglansky; D Greenberg; O Abramson; P M Mendelman; N Bohidar; P Yagupsky
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

7.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

Review 8.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease.

Authors:  D Bogaert; R De Groot; P W M Hermans
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

9.  Emergence of Streptococcus pneumoniae serogroups 15 and 35 in nasopharyngeal cultures from young children with acute otitis media.

Authors:  Judith M Martin; Alejandro Hoberman; Jack L Paradise; Karen A Barbadora; Nader Shaikh; Sonika Bhatnagar; Timothy Shope; Stan L Block; Mary Ann Haralam; Marcia Kurs-Lasky; D Kathleen Colborn; Michael Green
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

10.  Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

Authors:  Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

View more
  7 in total

1.  Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world.

Authors:  Yadong A Cui; Harshila Patel; William M O'Neil; Se Li; Patricia Saddier
Journal:  Hum Vaccin Immunother       Date:  2017-01-26       Impact factor: 3.452

2.  High Prevalence of Asymptomatic Nasopharyngeal Carriage Rate and Multidrug Resistance Pattern of Streptococcus pneumoniae Among Pre-School Children in North Showa Ethiopia.

Authors:  Mihret Tilahun; Mesfin Fiseha; Endris Ebrahim; Seada Ali; Melaku Ashagrie Belete; Abdurahaman Seid; Wondmagegn Demsiss; Alemu Gedefie; Selamyhun Tadesse; Chernet Belayhun
Journal:  Infect Drug Resist       Date:  2022-08-05       Impact factor: 4.177

3.  Nasopharyngeal pneumococcal carriage rates among HIV-infected adults following widespread pediatric use of conjugate pneumococcal vaccine-13.

Authors:  Theresa D Feola; Cynthia A Bonville; Donald A Cibula; Sherly Jose; Geetha Nattanmai; Joseph B Domachowske; Manika Suryadevara
Journal:  Hum Vaccin Immunother       Date:  2016-05-24       Impact factor: 3.452

4.  Pneumococcal Colonization in the Familial Context and Implications for Anti-Pneumococcal Immunization in Adults: Results from the BINOCOLO Project in Sicily.

Authors:  Fabio Tramuto; Emanuele Amodio; Giuseppe Calamusa; Vincenzo Restivo; Claudio Costantino; Francesco Vitale
Journal:  Int J Mol Sci       Date:  2017-01-06       Impact factor: 5.923

5.  Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014.

Authors:  Carmen Sheppard; Norman K Fry; Shazad Mushtaq; Neil Woodford; Rosy Reynolds; Regina Janes; Rachel Pike; Robert Hill; Maimuna Kimuli; Peter Staves; Michel Doumith; Timothy Harrison; David M Livermore
Journal:  Euro Surveill       Date:  2016-12-15

6.  Changes in the Serotype Distribution among Antibiotic Resistant Carriage Streptococcus pneumoniae Isolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine.

Authors:  Joon Kee Lee; Ki Wook Yun; Eun Hwa Choi; Sun Jung Kim; Seong Yeon Lee; Hoan Jong Lee
Journal:  J Korean Med Sci       Date:  2017-09       Impact factor: 2.153

7.  Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study.

Authors:  J Lourenço; U Obolski; T D Swarthout; A Gori; N Bar-Zeev; D Everett; A W Kamng'ona; T S Mwalukomo; A A Mataya; C Mwansambo; M Banda; S Gupta; N French; R S Heyderman
Journal:  BMC Med       Date:  2019-12-05       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.